Leonard S. Schleifer - 17 May 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Bd. Co-Chair, President & CEO, Director
Signature
/s/**Leonard S. Schleifer
Issuer symbol
REGN
Transactions as of
17 May 2024
Net transactions value
-$22,355,714
Form type
4
Filing time
17 May 2024, 17:57:52 UTC
Previous filing
15 May 2024
Next filing
10 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale $22,215,564 -22,687 -4.6% $979.22 467,020 17 May 2024 Direct F1, F2
transaction REGN Common Stock Sale $140,150 -143 -0.03% $980.07 466,877 17 May 2024 Direct F1, F3
holding REGN Common Stock 157,552 17 May 2024 2023 GRAT
holding REGN Common Stock 5,932 17 May 2024 By 401(k) Plan
holding REGN Common Stock 64,985 17 May 2024 By Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024.
F2 Represents volume-weighted average price of sales of 22,687 shares of Company stock on May 17, 2024 at prices ranging from $979.00 to $979.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price.
F3 Represents volume-weighted average price of sales of 143 shares of Company stock on May 17, 2024 at prices ranging from $980.01 to $980.20. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price.